Beyond Meat Inc (NASDAQ:BYND) shares are trading lower Monday afternoon, giving back part of last week's rally after the plant-based food maker announced an expansion of its new Beyond Immerse sparkling protein drink line. Here’s what investors need to know.Beyond Meat stock is feeling bearish pressure. What’s pressuring BYND stock?Low-Calorie Protein Drinks Target Health ConsumersThe El Segundo, California–based company said late last week that it is rolling out four limited-time flavors — Cherry Berry, St ...

Tax software makes filing a return simple. While platforms are designed to be straightforward and user-friendly, questions often surface that can cause some confusion. According to two tax experts, some of the most confusing questions have to do with safety, whether the software will catch all available credits and deductions, and whether or not it’s a good option for businesses. Here are some common questions about tax software. Is It Safe? “The most common question I hear from people about tax softw ...

We did not deliver everything we set out to do in 2025. Production growth came more slowly than expected and net debt ended the year higher than planned. But we laid the groundwork to deliver in 2026, and we are already seeing strong progress and momentum this year. Turning to Slide 5. As I said on the previous slides, our agenda remains consistent, our key priorities have not changed. We have had a strong start to 2026 with good progress across production, costs, and the balance sheet. Starting with produc ...

TORONTO, ONTARIO / ACCESS Newswire / March 2, 2026 / Electrovaya Inc. ("Electrovaya" or the "Company") (NASDAQ:ELVA)(TSX:ELVA),a lithium-ion battery technology and manufacturing company, is pleased to announce that all of the resolutions that shareholders were asked to consider at its 2025 Annual General Meeting held on February 27, 2026 in Toronto, Ontario, were approved. The six directors named in the management information circular of the Company, being Dr. Sankar Das Gupta, Dr. Raj Das Gupta, Dr. James ...

today. Your wallet will thank you later.[David Beren]| 1 hour ago## If you make $400k per year, don't retire at 65 unless you have this much saved[Christy Bieber]| 1 hour ago## I Didn't Save for Retirement - What Now?## Continue Reading## 17 Analysts See 42% Upside in AeroVironment as March Earnings Approach[David Beren | Feb 25, 2026 at 6:08 AM EST AeroVironment (NASDAQ:AVAV) might not be a household name, and the stock's 3% decline over the past week, along with its…]## AeroVironment Adds Soft Guidance to ...

If you ask me for a reason I'd buy Pfizer (NYSE: PFE) stock and never sell it, I certainly have one -- because I've already bought into Pfizer, and I have no plans to sell it. Here's a look at why I invested in Pfizer, and why you might want to, as well. Image source: Getty Images. Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue » Meet P ...

Performance growth was driven by the successful commercialization of Calcasieu Pass and the rapid commissioning ramp at Plaquemines, which is now producing over one cargo per day. Management attributes their competitive advantage to a modular construction approach and in-house EPC functions, which reportedly reduce construction timelines by half compared to industry peers. Operating and maintenance costs are approximately 30% below industry averages, a result of massive data capture from over 500,000 ...

Operational excellence initiatives at Kinetic led to the highest consumer fiber gross adds ever and the best churn levels since the pandemic.Management is aggressively transitioning the revenue mix, with fiber expected to overtake legacy copper and TDM services as the majority of revenue by 2026.Strategic positioning focuses on 'insurgent' growth, prioritizing high-density fiber builds in Tier 2 and Tier 3 markets where the company has a first-mover advantage.Achieved record new bookings in Q4 2025, includi ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Pomdoctor Limited due to allegations of securities law violations, encouraging affected investors to contact them for legal options [2][4]. Group 1: Allegations Against Pomdoctor - The complaint alleges that Pomdoctor and its executives made false and misleading statements and failed to disclose critical information regarding a fraudulent stock promotion scheme [4]. - Specific allegations include the use of social media misinformation, insider trading through offshore accounts, and omission of artificial trading activity that inflated stock prices [4]. - As a result of these actions, the positive statements made by the company about its business and prospects were deemed materially misleading [4]. Group 2: Stock Performance - Pomdoctor's share price experienced a significant decline from approximately $0.50 per share on December 10, 2025, to about $0.38 per share on December 11, 2025, marking a drop of roughly $0.12 per share or approximately 24% in one trading session [5]. - This decline was attributed to increased volatility and selling pressure amid investor concerns regarding the company's financial performance and valuation [5]. Group 3: Legal Proceedings - Investors who purchased Pomdoctor securities between October 9, 2025, and December 11, 2025, are reminded of the April 13, 2026, deadline to seek the role of lead plaintiff in the federal securities class action against the company [2][6]. - The lead plaintiff is defined as the investor with the largest financial interest in the relief sought, who will direct and oversee the litigation on behalf of the class [6].

Achieved a defining milestone of financial self-sustainability, effectively removing the need for external funding to support the current strategy and pipeline. Recorlev served as the primary growth engine, nearly doubling its patient base to approximately 700 patients by year-end 2025. Gvoke provided durable and predictable revenue growth of 14% for the full year, supported by broad market access and alignment with treatment guidelines. Keveyis outperformed expectations by increasing the average nu ...